Source: International Congress 2015 – Interstitial lung diseases II
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Nikolas Manitsopoulos (Athens, Greece), Nikolaos Manitsopoulos, Anastasia Kotanidou, Christina Magkou, Ioanna Ninou, Xia Tian, Vassilis Aidinis, Ralph Schermuly, Stylianos Orfanos. Treprostinil administration attenuates bleomycin-induced lung fibrosis in mice. Eur Respir J 2015; 46: Suppl. 59, 3837

Member's Comments

No comment yet.

Related content which might interest you: 17(R)-resolvin D1 attenuates bleomycin-induced lung fibrosis in mice Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases Year: 2013 Selective endothelin-A receptor blockade attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 New approach to the treatment of bleomycin-induced lung fibrosis using pulmonary surfactant as pirfenidone carrier into the lung Source: International Congress 2015 – Inflammation and remodelling in lung disease Year: 2015 Sulforaphane attenuates lung fibrosis in bleomycin-induced pulmonary fibrosis via inhibition of TGF-beta/Smad signaling Source: International Congress 2014 – ILDs 4 Year: 2014 Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Novel biomarkers in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Effects of NecroX compounds on bleomycin-induced pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 17(R)-resolvinD1 improves MMP-9/TIMP-1 imbalance leading to amelioration of pulmonary fibrosis in mice Source: International Congress 2016 – ILD pathogenesis Year: 2016 Effect of intratracheal administration of adipose-derived stromal cells on bleomycin-induced lung injury in a rat model Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 Olodaterol attenuates bleomycin induced lung fibrosis in mice Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016 Role of dendritic cells in pulmonary fibrosis in mice Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Interdependence of HIF1alpha /TGFbeta1 activity in induction of pulmonary fibrosis Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases Year: 2013 Specialized-proresolving mediators and trancriptomic signatures in bleomycin-induced lung fibrosis Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 Increased levels of oxidative stress markers in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 Thymosin beta4 protects mice from bleomycin-induced damage in the lung Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Pirfenidone attenuates myofibroblast differentiation during insufficient mitophagy Source: International Congress 2016 – IPF pathogenesis Year: 2016 Aerobic training inhibits bleomycin-induced pulmonary fibrosis in BALB/c mice Source: International Congress 2014 – Animal models: asthma, COPD and beyond Year: 2014 Severe lung inflammation is a feature of IPF Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Ghrelin protects against bleomycin-induced pulmonary fibrosis in mice Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017